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INTRODUCTION
Mycophenolic acid (MPA) is an effective and widely used immunosuppressant in human medicine. It is a fermentation product of a Penicillium species that was discovered over a century ago, but was not used for clinical purposes until the mid1990s (Bullingham et al., 1998; Miles et al., 2005; Lange et al., 2008) . Available pharmaceutical preparations include either mycophenolate mofetil (an ester prodrug) or mycophenolate sodium (salt). Clinical uses in dogs include prevention of organ transplant rejection and treatment of various autoimmune disorders (Whitley & Day, 2011) . Mycophenolate mofetil has gained popularity in treating canine patients, as it is widely available in various oral and intravenous formulations, making it desirable for use in veterinary patients with immune-mediated diseases (Wang et al., 2013; West & Hart, 2014) . MPA has been studied extensively in humans, and to a lesser extent in dogs. However, apart from one case report of the clinical use of mycophenolate mofetil in two cats (Bacek & Macintire, 2011) , and one in vitro study showing effects of MPA on feline lymphocytes (Kyles et al., 2000) , there are no studies establishing MPA safety or efficacy in cats.
MPA is a noncompetitive reversible inhibitor of the enzyme, inosine monophosphate dehydrogenase (Whitley & Day, 2011; Abd Rahman et al., 2013) . Inosine monophosphate dehydrogenase is a rate-limiting enzyme in the de novo purine synthesis pathway, which is essential for T-and B-cell proliferation and differentiation of T-cytotoxic cells (Whitley & Day, 2011) . The immunosuppressant effects of MPA are terminated by conjugative metabolism in liver and some other tissues, followed by excretion of these metabolites into urine and bile (Bullingham et al., 1998; Abd Rahman et al., 2013) . In humans, MPA is primarily conjugated with uridine diphosphate (UDP)-glucuronic acid to form the stable pharmacologically inactive phenolic glucuronide and much smaller amounts of the acyl glucuronide (Miles et al., 2005; Picard et al., 2005) . In humans, minor MPA metabolic pathways include UDP-glucose conjugation to form phenolic and acyl glucosides (Shipkova et al., 2001; Picard et al., 2005) . UDP-glucose acts as a cofactor by transferring D-glucose to the substrate, forming b-D-glucosides (Testa & Kramer, 2008) . Glucosidation is an understudied metabolic pathway for drugs that occurs in species other than humans and was notably described in the cat by Carro-Ciampi et al., 1985 , when evaluating barbiturate metabolism.
Glucuronidation occurs primarily in the liver and is catalyzed by a subset of the UDP-glycosyltransferase (UGT) enzymes that are all contained within the UGT1A, UGT2A, and UGT2B subfamilies (Court et al., 2012) . Nineteen UGT1A, UGT2A, and UGT2B subfamily enzymes have been identified in humans, which differ in substrate selectivity and tissue expression levels (Court et al., 2012) . In human liver, MPA phenol glucuronide is formed primarily by UGT1A9, while the acyl glucuronide is formed mainly by UGT2B7 (Shipkova et al., 2001; Girard et al., 2004) . The enzymes mediating formation of the MPA glucosides remain to be determined.
Substantial differences in the presence and expression of UGT enzymes occur between species (Court et al., 2012; Court, 2013) . Compared with humans and dogs, cats lack several UGTs normally expressed in liver including UGT1A6 and UGT1A9 which explains in large part their sensitivity to the adverse effects of aromatic medications such as acetaminophen as these enzymes are required for detoxification and elimination by glucuronidation (Court, 2013) . As UGT1A9 plays a major role in MPA glucuronidation in humans, it is possible that cats may lack the capacity for efficient MPA glucuronidation, thereby decreasing drug clearance and increasing the risk for adverse effects.
The aim of this study was to determine between-and within-species differences in MPA conjugation by glucuronidation and glucosidation using liver microsomes from humans, dogs, and cats. Our primary hypothesis was that cats would glucuronidate MPA more slowly than humans and dogs. We evaluated the formation of the known major (phenol glucuronide) and minor (acyl glucuronide, phenol glucoside) MPA conjugates. Human-, dog-, and cat-pooled liver microsomes
MATERIALS AND METHODS

Chemicals and reagents
MPA
Liver microsomes were prepared from frozen human, cat, and dog livers by differential centrifugation as described by Court et al. (1997) . The pooled liver microsomes were collected from the Washington State University pharmacogenomics tissue bank with Institutional Animal Care and Use Committee and Institutional Review Board approval. The human samples (n = 48) were collected from liver transplants that had failed or from surgical liver resections from the University of Chicago, the National Disease and Research Interchange, the International Institute for the Advancement of Medicine, and the University of Pittsburg (Court, 2010) . There were 26 dog liver samples from Beagles, Greyhounds, and mixed-breed dogs (19 males and seven females). Sixteen cat liver samples were used from domestic short hair cats, (11 males and five females). The liver microsomes were collected from these untreated purpose-bred research animals or random-sourced healthy animals that were euthanized for reasons unrelated to this study. All liver microsomes preparations were stored at À80°C until use.
Liver microsomes incubations
Human, dog, and cat liver microsomes (0.1 mg/mL final volume with 50 mM pH 7.4 phosphate buffer) were incubated in 1.5 mL polypropylene tubes in the presence of MPA (10-1000 lM), alamethicin (50 lg/mL), magnesium chloride (5 mM), and either 5 mM UDP-glucuronic acid or 5 mM UDPglucose (or both for individual cat liver microsomes) for 15 min at 37°C in a water bath. The reaction was stopped by removing the tubes from the water bath at 15 min and adding 200 lL of acetonitrile containing 5% acetic acid, vortexing, and placing on ice. After adding 100 lL of a 20 lM solution of the internal standard (MPA phenol glucuronide-D 3 ) dissolved in methanol, the mixture was vortexed and centrifuged for 10 min at 15 000 g. The supernatant was transferred to 2-mL polypropylene tubes and dried for approximately 2 h in a centrifugal vacuum. Once dried, 200 lL of 2 mM ammonium formate (pH 4.5) in water with 25% acetonitrile was added. The samples were centrifuged for 10 min at 15 000 g, and the supernatant was transferred to a 96-well polypropylene plate for analysis by HPLC-MS.
HPLC-MS quantitation of MPA glucuronide and glucoside
The HPLC apparatus consisted of an Agilent Model 1100 with Leap CTC-PAL autosampler and 2 9 150 mm Phenomenex Synergi 4 l Fusion-RP 80A column. The MS detector was an AB-Sciex API4000 triple quadruple instrument and negative ion mass transitions monitored included 495.5?319 (MPA phenol glucuronide and MPA acyl glucuronide), 498.5?322 (MPA phenol glucuronide-D 3 ), and 481.5?319 (MPA phenol glucoside). MPA was also detected with a negative ion mass of 319. The HPLC mobile phase consisted of a variable mixture of 2 mM ammonium formate buffer in water (mobile A) with acetonitrile (mobile B) run at a combined flow rate of 350 lL/ min. The initial mobile A:B mix (v/v) was 85:15 at the run start, which linearly changed with time to 10:90 at 5 min and returned to 85:15 at 6 min, and remained at that ratio until the end of the run at 10 min. Retention times after the start of the run were 4.7 min for MPA phenol glucuronide and MPA phenol glucuronide-D 3, 5.1 min for MPA acyl glucuronide and MPA phenol glucoside, 5.5 min for MPA acyl glucoside, and 6.5 min for MPA. The lower limits of quantitation were 500 nM, 300 nM, and 300 nM concentration in the incubation for MPA phenol glucuronide, MPA acyl glucuronide, and MPA glucoside, respectively. The limits of detection (defined as 10 times the baseline signal) were 50, 75, and 30 nM concentration in the incubation for MPA phenol glucuronide, MPA acyl glucuronide, and MPA phenol glucoside. Preliminary studies found that human liver microsomes produced small amounts of the MPA acyl glucoside, while cat and dog liver microsomes did not produce any detectable MPA acyl glucoside despite producing large amounts of the phenol glucoside. Consequently, the MPA acyl glucoside was not evaluated further. The amount of MPA phenol glucuronide, MPA acyl glucuronide, and MPA phenol glucoside formed in the incubation were calculated from standard curves generated using samples containing known amounts of pure standards and internal standard.
Enzyme activities, kinetics, and statistical analysis
Enzyme activities were calculated by dividing the amount of metabolite formed in each incubation tube by the amount of microsomal protein and the incubation time. The amount of metabolite formed was confirmed to be linear with respect to incubation time up to 30 min and protein concentration up to 0.4 mg/mL at 100 lM MPA concentration for pooled human, dog, and cat liver microsomes. Enzyme kinetic parameters including the Michaelis-Menten constant (Km) and the maximal enzyme velocity (Vmax) were derived from triplicate determinations by nonlinear regression analysis (Sigmaplot version 12.0, Systat Software, San Jose, CA, USA). Enzyme intrinsic clearance (CLint) was calculated by dividing the Vmax by the Km values for each activity and each species assayed. Differences in enzyme kinetic values between species for each activity were evaluated by analysis of variance (ANOVA) with multiple comparisons testing vs. control (cat liver microsomes) using Dunnett's method (Sigmaplot version 12.0). A P value less than 0.05 was considered statistically significant. Unless otherwise indicated, the data are expressed as means AE 1 SD.
RESULTS
Comparative enzyme kinetics of MPA glucuronidation and glucosidation by liver microsomes Figure 1 shows plots of MPA metabolite formation rates measured using substrate concentrations from 10 to 1000 lM in pooled cat (n = 16), dog (n = 26), and human (n = 48) liver microsomes as well as curves fitted to these data using the Michaelis-Menten model. All data were well described by the simple one-enzyme Michaelis-Menten equation. Derived enzyme kinetic parameters (Vmax and Km) are given in Table 1 for pooled liver microsomes from each species studied. The calculated CLint values are expressed as both the absolute clearance (mL/kg/min) for each pathway, and also as the relative clearance (percentage of summed clearance by conjugation), to enable comparisons of each metabolic pathway within and between species.
In agreement with our initial hypothesis (Table 1) , phenol glucuronidation of MPA was substantially lower in cat livers (P = 0.001, ANOVA) with CLint values that averaged only 17% of dog livers (P = 0.002, Dunnett's test) and 15% of human livers (P < 0.001, Dunnett's test). However, acyl glucuronidation CLint of MPA in cat livers was not different from dog and human livers (P > 0.05, ANOVA). Interestingly, phenol glucosidation CLint of MPA in cat livers was similar to that of dog livers (P > 0.05, Dunnett's test) and more than 20 times that of human livers (P < 0.001, Dunnett's test).
When MPA CLint values for all pathways evaluated were summed for each species (Table 1) , the total predicted CLint for cat liver microsomes (15 mL/kg/min) was 43% that of dog (35 mL/kg/min; P = 0.002, Dunnett's test) and 58% of human (26 mL/kg/min) liver microsomes (P = 0.033, Dunnett's test). The relative contribution of each pathway to total measured conjugation varied substantially between species in that phenol glucuronidation predominated in dog (56%) and human (91%) liver microsomes, while phenol glucosidation was the predominant pathway in cat (60%) liver microsomes (Fig. 2) .
Variation in MPA conjugation between individual cat liver microsomes
Metabolite formation rates were then determined for the 16 individual cat liver microsome fractions that constituted the pooled microsomes at a substrate concentration of 100 lM to evaluate individual variability (Fig. 3) . Activities determined for pooled dog and human liver microsomes using the same MPA concentration are included for comparison. Mean AE SD (coefficient of variation as a percent; CV%) activities for formation of MPA phenol glucuronide, MPA acyl glucuronide, and MPA phenol glucoside were 0.33 AE 0.15 (44%), 0.20 AE 0.14 (67%), and 0.41 AE 0.12 (30%) nmoles/min/mg protein, respectively. Maximum over minimum fold variation in activities were highest for acyl glucuronidation (11-fold), intermediate for phenol glucuronidation (5.5-fold), and lowest for phenol glucosidation (threefold). However, when the three conjugation pathways were summed, the fold variation was modest (threefold), ranging from 0.5-1.5 nmoles/min/mg protein with a mean AE SD (CV%) of 0.95 AE 0.33 (35%) nmoles/min/mg protein.
DISCUSSION
MPA is a potentially useful immunosuppressant drug in cats (Kyles et al., 2000; Bacek & Macintire, 2011) . However, given the major role for glucuronidation in MPA metabolism in humans, there are concerns that the known deficiencies of UGT1A9 (and other UGTs) in cats could also cause deficient MPA glucuronidation, potentially delaying MPA clearance and leading to MPA accumulation and toxicity. Without a good understanding of MPA clearance in cats, it is not possible to determine the dose required to achieve an effective and safe blood concentration in the feline species. In support of our primary hypothesis, we did find significantly (over five times) slower formation of the MPA phenol glucuronide in cats vs. dogs and humans. However, we also found a much smaller difference (about two times) in overall metabolism of MPA by conjugation (glucuronidation plus glucosidation) when comparing cat liver microsomes with dog and human liver microsomes despite significantly reduced MPA phenol glucuronide formation in cats. This occurred in large part because of the substantially higher relative contribution of glucosidation to total MPA conjugation in cat liver microsomes (60%) when compared with dog (34%) and especially human (2%) liver microsomes.
Although glucosidation is the major pathway for conjugative metabolism of xenobiotics in nonvertebrate species (including insects and plants), glucuronidation is the dominant conjugative clearance mechanism in all vertebrates studied to date (Shipkova et al., 2001; Huang et al., 2008; Wang et al., 2014; Bock, 2016) . This is despite the ready availability of UDPglucose as a cofactor in hepatocytes. Although there are relatively few examples of drugs that are glucosidated to any significant extent in mammals, some of them include: morphine, phenobarbital, amobarbital, ibuprofen, and varenicline (Kalow et al., 1979; Arima & Kato, 1990; Bernus et al., 1994; Nandi & Soine, 1997; Chau et al., 2014) . In most instances, the same drugs are also metabolized by glucuronidation with higher efficiency, although a few exceptions have been identified, including acyl glucosidation of panoprofen in mice (Arima & Kato, 1990) , and N-glucosidation of amobarbital and phenobarbital in humans (Kalow et al., 1979; Bernus et al., 1994; Nandi & Soine, 1997) . In future studies, one should consider the potential for glucosidation (vs. glucuronidation) as a major alternate clearance pathway for drugs used in cats.
The specific enzyme-mediating glucosidation of MPA (either phenol or acyl) has not yet been determined. Results so far implicate UGT2B7 as the main enzyme that glucosidates morphine (Chau et al., 2014) , ibuprofen (Buchheit et al., 2011) , an experimental endothelin antagonist (Tang et al., 2003) , and hyodeoxycholic acid (Mackenzie et al., 2003) , while UGT2B15 was found to glucosidate an experimental aldose reductase inhibitor (Toide et al., 2004) . Our results indicate that cats may express a UGT that has a higher catalytic efficiency for glucosidation of MPA than those expressed by humans and dogs. Apart from the UGT1 and UGT2 family of enzymes that most efficiently use UDP-glucuronic acid as the cosubstrate, several UGTs have been identified in humans that primarily use other UDP-sugars as the cosubstrate including UGT3A1, UGT3A2, and UGT8. Of these, UGT3A2 appears to have the highest efficiency in using UDP-glucose for conjugating xenobiotics (MacKenzie et al., 2011) . However, although human Phenol glucosidation CLint of MPA in cats was over 20 times that of humans (P < 0.001, Dunnett's test), but similar to that of dogs (P > 0.05, Dunnett's test). **Total conjugation for cats was 43% that of dogs (P = 0.002, Dunnett's test) and 58% that of humans (P = 0.033, Dunnett's test). Fig. 2 . The structures and known metabolic pathways responsible for activation of mycophenolate mofetil (MPF) to mycophenolic acid (MPA) by esterases, and conjugative metabolism of MPA to the phenol glucuronide by UGT1A9, acyl glucuronide by UGT2B7, and phenol glucoside by an undetermined UGT. Also shown are the relative amounts of each conjugated metabolite formed by pooled human, dog, and cat liver microsomes in this study.
UGT3A2 is expressed in the kidney, it is poorly expressed in the liver and intestines.
We also quantified differences in MPA metabolism between different cat livers. Although the variability in total conjugation metabolism was quite modest (only about threefold), the variation in MPA acyl glucuronide was quite substantial (11-fold). Acyl glucuronide metabolites tend to be unstable and capable of covalently binding to proteins (Picard et al., 2005) . MPA acyl glucuronide, unlike MPA phenol glucuronide, acts as an uncompetitive IMPDH inhibitor, but has lower enzyme inhibitory potential than MPA (Gensburger et al., 2009) . Acyl glucuronide metabolites can be secreted into the bile and then re-deposited into the intestines vs. eliminated, thereby increasing exposure of this active metabolite to the intestine, possibly increasing the chance of gastrointestinal side effects (Picard et al., 2005) . Furthermore, differences in MPA acyl glucuronide have been associated with the occurrence of MPAassociated diarrhea in people (Picard et al., 2005) . Consequently, if diarrhea is also found to occur as a side effect in some cats, this could be explained by variability in acyl glucuronide formation.
There are several limitations to our studies that should be noted. Our study involved liver microsomes as the liver is a primary organ involved in drug glucuronidation and MPA metabolism. However, significant MPA conjugation has also been reported for human kidney and intestinal mucosa microsomes with specific activities that are similar to liver activities (Bowalgaha & Miners, 2001; Shipkova et al., 2001) . Consequently, it has been suggested that conjugation in intestines and kidney may be important for presystemic extraction or urinary clearance of MPA, respectively. However, extrapolation of data collected from experiments using kidney and intestinal microsomes to the whole organ indicates that MPA clearance is 20-40 times greater in the liver compared with kidney and intestines suggesting that the effect on extraction or clearance may be limited, at least in people (Bowalgaha & Miners, 2001) . Finally, although our data suggests that MPA should be cleared by conjugation in the liver in cats at a rate that is only about half of the rate in dogs and humans, the predictive value of this model is limited. Thus, pharmacokinetic studies will be needed to ascertain whether there are species differences in MPA disposition and clearance. , and phenol glucoside (gray bars) measured at 100 lM MPA concentration using microsomes prepared from 16 different domestic short hair cat livers in triplicate in 1 experiment. Individual sample results (identification (ID) numbers 1-16) were sorted from lowest to highest (left to right) total conjugation activity. Also shown for comparison are the same activities for pooled dog and human liver microsomes measured at the same MPA concentration. The mean values for the dog and human were derived from three experiments.
